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Abstract 
Nitric oxide (NO) can be generated endogenously via NO synthases or via the diet following 
the action of symbiotic nitrate-reducing bacteria in the oral cavity. Given the important role 
of NO in smooth muscle control there is an intriguing suggestion that cardiovascular 
homeostasis may be intertwined with the presence of these bacteria. Here, we measured the 
abundance of nitrate-reducing bacteria in the oral cavity of 25 healthy humans using 16S 
rRNA sequencing and observed, for 3.5 hours, the physiological responses to dietary nitrate 
ingestion via measurement of blood pressure, and salivary and plasma NO metabolites. We 
identified 7 species of bacteria previously known to contribute to nitrate-reduction, the most 
prevalent of which were Prevotella melaninogenica and Veillonella dispar. Following dietary 
 
 
nitrate supplementation, blood pressure was reduced and salivary and plasma nitrate and 
nitrite increased substantially. We found that the abundance of nitrate-reducing bacteria was 
associated with the generation of salivary nitrite but not with any other measured variable. To 
examine the impact of bacterial abundance on pharmacokinetics we also categorised our 
participants into two groups; those with a higher abundance of nitrate reducing bacteria 
(>50%), and those with a lower abundance (<50%). Salivary nitrite production was lower in 
participants with lower abundance of bacteria and these individuals also exhibited slower 
salivary nitrite pharmacokinetics. We therefore show that the rate of nitrate to nitrite 
reduction in the oral cavity is associated with the abundance of nitrate-reducing bacteria. 
Nevertheless, higher abundance of these bacteria did not result in an exaggerated plasma 
nitrite response, the best known marker of NO bioavailability. These data from healthy young 
adults suggest that the abundance of oral nitrate-reducing bacteria does not influence the 
generation of NO through the diet, at least when the host has a functional minimum threshold 
of these microorganisms.   
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Introduction 
NO is a multifunctional signalling molecule which is involved in various biological processes 
such as; host defence [1], regulation of mucosal blood flow and mucus generation [2], 
regulation of smooth muscle contraction [3], cerebral blood flow [4], glucose homeostasis [5], 
and mitochondrial function [6]. Ingestion of inorganic NO3- from sources such as green leafy 
vegetables and roots has been consistently shown to increase plasma and salivary [NO3-] [7] 
and augment NO bioavailability [8]. In this pathway, NO3- is rapidly absorbed in the upper 
gastrointestinal tract and enters the circulation [9] before it is subsequently concentrated in 
the saliva [10], [11] and a proportion reduced to NO2-. Salivary NO2- can be further reduced to 
 
 
nitric oxide (NO) in certain physiological conditions such as hypoxia or stored in the blood 
and tissues for use when endogenous production of NO via NO synthases (NOS) is limited 
[12]. As a consequence, ingestion of inorganic NO3- may elicit a myriad of positive biological 
effects likely mediated by an increased NO bioavailability. Some studies have demonstrated 
that ingestion of NO3-írich beetroot juice can reduce blood pressure (BP) [13], enhance 
endothelial function [14], protect against ischaemic injury [15], and improve exercise 
performance [16] although these effects are not consistently observed [17], [18], [19].  
 
The reduction of NO3- to NO2- in saliva is achieved through the action of certain microbes 
which reside in the oral cavity [20], [21]. The whole human microbiome is characterised by 
body site-specific microbial ecosystems capable of exerting effects on their host through 
production of metabolites, immune responses, and gene expression [22].  Some microbes live 
in symbiosis with their host and can significantly contribute to health [23], [24]. Conversely, 
low diversity of microbial species resulting in dysbiotic states, have been linked to a number 
of adverse health conditions including; metabolic syndrome, allergies, asthma, obesity, and 
cardiovascular disease amongst others [25].  The oral cavity is heavily colonised by microbes 
and is one site where a symbiotic relationship between humans and bacteria is clearly 
evident.  
 
A series of studies have confirmed the importance of commensal bacteria to the mammalian 
enterosalivary cycle, and NO bioavailability. These studies show consistently that rinsing the 
oral cavity with chlorhexidine anti-bacterial mouthwash disrupts bacterial enzymatic activity 
and abolishes the BP lowering effects associated with dietary NO3- ingestion [26]±[28]. Hyde 
and colleagues [21] recently analysed oral microflora from a small sample of healthy human 
participants (n = 6) and identified 14 bacterial candidate species that are thought to contribute 
 
 
to NO3- reduction. The majority of operational taxonomic units (OTUs) with NO3- reducing 
capability originated from the genera Granulicatella, Actinomyces, Veillonella, Prevotella, 
Neisseria, and Haemophilus. Other studies  have also associated OTUs from the genera 
Rothia and Staphylococcus with NO3- reduction [20], [29]. Despite emerging evidence linking 
NO3- reducing bacteria with cardiovascular homeostasis no study has explored the 
relationship between the abundance of NO3- reducing bacteria in the oral cavity and the 
capacity to process dietary NO3- in vivo. This is important because the conversion of NO3- 
from the diet to NO2- is known to be profoundly variable [30] and the abundance of NO3- 
reducing bacteria may be a rate-limiting step in this process.  
 
Therefore, our primary objective was to perform descriptive analysis of the abundance and 
diversity of oral NO3- reducing bacteria in a larger cohort than previously utilised [21]. The 
secondary objective was to determine the association between the abundance of known NO3- 
reducing bacteria with cardiovascular variables and NO biomarkers in blood and saliva. A 
further objective was to determine whether participants with a higher abundance of NO3- 
reducing bacteria had different salivary and plasma NO pharmacokinetics following ingestion 
of dietary NO3- compared to those with a lower abundance. 
 
Methods  
Participants 
Twenty five healthy adults (age 27 ± 7 years, stature 172 ± 9 cm, body mass 75 ± 15 kg, 11 
female) volunteered and provided written informed consent prior to participating in the study. 
Ethical approval was provided by the School of Science Ethics Committee at The University 
of the West of Scotland.  All participants were in good cardiovascular and oral health, did not 
 
 
report any habitual use of antibacterial mouthwash, were free from non-prescription 
medicines known to interfere with stomach acid production, and were not taking any 
prescribed medication. Cardiovascular health status was confirmed by completion of a 
medical questionnaire and The :RUOG +HDOWK 2UJDQLVDWLRQ¶V RUDO KHDOWK TXHVWLRQQDLUH was 
used to ascertain oral health status.  All procedures were conducted in accordance with the 
Declaration of Helsinki 1974 and its later amendments.  
 
Experimental Design  
Each participant attended the laboratory on one occasion for this cross-sectional study.  Prior 
to the trial, participants were briefed on procedures and provided with an adapted version of 
the National Institutes of Health daily food list. The questionnaire was adapted to 
differentiate between high, medium, and low NO3- containing foods [31]. Participants were 
asked to record their diet for seven days prior to arrival at the laboratory and instructed to 
maintain a normal dietary routine. Participants arrived at the laboratory on the morning of the 
trial in a fasted and euhydrated state after consuming 500 ml of water. Prior to the trial, 
participants were instructed to avoid strenuous exercise for 24 h and caffeine for 12 h. On the 
morning of the trial participants were requested not to brush their teeth or tongue and not to 
use mouthwash or chew gum. Participants provided verbal assurance of their compliance 
with these instructions.  
 
Procedures 
On arrival at the laboratory, stature and body mass were recorded. Participants then lay 
supine for the remainder of the experiment. During the first 30 min a cannula was inserted 
 
 
into one of the forearm veins and a tongue scrape sample collected. No other physiological 
measurements were collected for 30 min to ensure plasma [NO2-] had stabilised following the 
change in body posture [32]. Following this initial phase, baseline measurements of BP and 
heart rate (HR) were recorded and samples of blood and saliva were collected. Participants 
then ingested 2 x 70 ml of NO3--rich beetroot juice (~12.4 mmol NO3-) (Pro-Elite Shot, James 
White Drinks Ltd., Suffolk, England) and physiological measurements were collected at 
regular intervals for the next 3.5 h (Fig. 1).  
 
Figure 1: Schematic diagram depicting time-course of data collection from 0 h to 3.5 h following the 
consumption of NO3--rich beetroot juice 
  
Blood Collection  
Venous blood was collected in 4 ml aliquots in tubes containing ethylenediaminetetraacetic 
acid (BD vacutainer K2E 7.2mg, Plymouth, U.K.). Plasma NO2- has been shown to peak, on 
 
 
average, at 2.5 h after ingestion of beetroot juice [33] so multiple blood samples were taken 
before and after this point. Samples of whole blood were immediately centrifuged for 10 min 
at 4000 rpm at 4°C (Harrier 18/80, Henderson Biomedical. UK) immediately following 
collection.  The plasma was then separated into two cryovials and immediately stored at -
80ͼC for later analysis of NO3- and NO2- content via ozone-based chemiluminescence. The 
cannula was flushed with 2 ml sterile 0.9% saline immediately following blood draws to keep 
the line patent. 
Saliva Collection 
Samples of unstimulated saliva were collected via an oral swab (Saliva Bio Oral Swab (SOS) 
Salimetrics, Pennsylvania, USA) placed under the tongue for 3 min. Samples of saliva were 
collected from 0.5 h onwards as previous data has shown salivary [NO2-] and [NO3-] may 
peak earlier than 1 h [28]. Swabs were then transferred to a collection tube (Sartedt, 
Aktiengesellschaft & Co, Numbrecht, Germany) and centrifuged at 4000 rpm for 10 min at 
4°C (Harrier 18/80, Henderson Biomedical. UK). Samples were then separated into two 
cryovials and immediately stored at -80ͼC for later analysis of NO3- and NO2-. 
 
Measurement of Salivary and Plasma [NO3-] and [NO2-] 
For the analysis of plasma NO2-, tri-iodide reagent comprised of 2.5 ml glacial acetic acid, 
PORIGHLRQLVHGZDWHU, and 25 mg sodium iodide, was placed in a glass purge vessel 
heated to 50°C and connected to the NO analyser (Sievers NOA 280i, Analytix, UK). A 
standard curve was created E\ LQMHFWLQJ  ȝ/ RI NO2- solutions at concentrations up to 
1000 nM. Plasma and saliva samples were thawed in a water bath at 37°C and 100µL of the 
thawed sample was injected immediately into the purge vessel, in duplicate. Saliva samples 
 
 
were diluted with deionised water at a ratio of 1:100 before injection. NO2- content was 
calculated via the area under the curve using Origin software (version 7.1). 
 
For the analysis of NO3-, vanadium reagent consisting of 24 mg of vanadium tri-chloride and 
3 ml of 1 M hydrochloric acid was placed into the purge vessel and was heated to 90°C. A 
standard curve was created by injecting 25-ȝ/NO3- solutions at concentrations up to 100 
µM. Plasma samples were de-proteinised using 1 M zinc sulfate (ZnSO4) at 1:10 w/v and 1 M 
sodium hydroxide (NaOH) at a 1:1 ratio. 200 µL of plasma was added to 400 µL of ZnSO4 
and 400 µL of NaOH. Each sample was vortexed for 30 s prior to being centrifuged for 5 min 
at 4000 rpm. Supernatant was then injected into the purge vessel and concentration calculated 
as described for NO2-.  
 
Heart Rate and Blood Pressure  
HR was continually monitored via telemetry (Polar Electro, Oy, Finland). Measurements of 
BP were recorded in triplicate by standard auscultation using an automated device (Orman 
M6, Intelli-Sense. Hoofdorp, the Netherlands).  Mean arterial pressure (MAP) was calculated 
using the following equation; 
MAP = (2 x diastolic BP + systolic BP) / 3 
 
Tongue Scrape and Bacteria Collection 
Bacteria were collected from the posterior dorsal surface of the tongue using a sterile metal 
tongue cleaner (Soul Genie, Health Pathways LLP, Uttar Pradesh, India). This area of the 
 
 
mouth has previously been shown to contain a high abundance of NO3- reducing bacteria as 
they favour the anaerobic environment provided by the deep crypts of the tongue [20]. The 
tongue cleaner was gently glided from the back to the front of the tongue until there was a 
visible coating on the instrument [21]. Tongue scrape samples were subsequently transferred 
via a sterile sample collection swab (Deltalab, S.L. Barcelona, Spain) to a MoBio Powersoil 
DNA Isolation Kit (MoBio Laboratories Inc. West Carlsbad, California) and immediately 
frozen at -80ͼC. Bacterial DNA was subsequently extracted using the MoBio Powersoil 
Isolation Kit according to the PDQXIDFWXUHU¶V guidelines. 
Bacterial Analysis 
DNA was transported to a commercial centre (HOMMINGS, The Forsyth Institute, Boston 
MA, USA) for sequencing analysis. A full description of the protocol is described in previous 
research [34]. In brief, the V3-V4 region of the bacterial genomic DNA was amplified using 
barcoded primers; ~341F (forward primer) 
(AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTCCTACGGGAGGCA
GCAG) and ~806R (reverse primer) 
CAAGCAGAAGACGGCATACGAGATNNNNNNNNNNNNAGTCAGTCAGCCGGACT
ACHVGGGTWTCTAAT). 
Samples (10 ± 50 ng) of DNA were PCR-amplified using V3-V4 primers and 5 
PrimeHotMaster Mix and purified using AMPure beads. A small volume (100 ng) of each 
library was pooled, gel-purified, and quantified using a bioanalyser and qPCR. Finally, 12pM 
of the library mixture, spiked with 20% Phix, was analysed on the Illumina MiSeq (Illumina, 
San Diego, CA).  
 
 
 
 
16s rRNA gene data analysis 
Quality filtered data received from the sequencing centre was further analysed for taxonomic 
classification and bacterial abundance using Qiime 1.8 [35]. One sample with less than 5000 
reads was discarded from further analysis. Sequences were clustered de novo and binned into 
OTUs based on 97% identity.  Taxonomy was assigned using RDP classifier trained to the 
GreenGenes database (October 2013 release). Singleton reads were removed from the 
dataset. In order to calculate alpha diversity metrics, the OTU table was sub-sampled to 
20090 reads per sample and repeated 5 times. The mean values were then calculated across 
the 5 sub-sampled OTU tables and used to calculate alpha diversity metrics. The smallest 
number of reads associated with any one sample was 20094 reads.  To analyse the effect of 
bacterial abundance on pharmacokinetic changes in response to NO3-, participants were split 
into two groups; those with a higher overall abundance (>50%) of NO3- reducing bacteria 
(High) and those with a lower abundance (<50%) (Low).  
 
Statistical Analysis 
Statistical Package for the Social Sciences (SPSS Version 22.0. Armonk, NY: IBM Corp) 
was used for statistical analysis. GraphPad Prism version 7 (GraphPad Software Inc., San 
Diego, USA) was used to create the figures. The distributions of data were assessed using the 
Shapiro Wilk test and non-parametric tests were used where data were not normally 
distributed. A one-way repeated measures ANOVA was used to assess changes in plasma and 
salivary NO3- and NO2-, and BP measurements.  
 
 
 
The association between the abundance of NO3- reducing bacteria and peak values of plasma 
and salivary NO YDULDEOHVZDVDQDO\VHGXVLQJ WKH6SHDUPDQ¶V UDQNFRUUHODWLRQFR-efficient. 
Peak delta values were defined as the value with the biggest change from baseline. The 
association between the abundance of NO3- reducing bacteria and the area under the curve for 
salivary nitrite across the experiment was calculated using the same method.  
 
Differences in bacterial abundances between Low and High groups were assessed using an 
independent t test. A two-factor mixed model ANOVA (group and time) was used to 
compare differences in BP and NO metabolites between groups and gender.  Data are 
presented as mean ± standard deviation unless otherwise stated. Statistical significance was 
declared when P  0.05. Probability values are expressed with 95% confidence intervals 
(95% CI) where appropriate. 
 
Results  
Ingestion of dietary NO3- raises plasma and salivary NO metabolites and lowers blood 
pressure 
Salivary and plasma NO2- and NO3- were increased at all time points compared to baseline 
(all P < 0.001), with the exception of plasma NO2- at 1 h (P = 0.1). Ingestion of beetroot juice 
significantly reduced SBP (P = 0.018, 95% CI 1 - 6 mmHg) and DBP (P = 0.045, 95% CI 1 - 
4 mmHg) at 2.5 h. MAP was significantly lower at 1.5 h (P = 0.01, 95% CI 1 - 5 mmHg), 2 h 
(P = 0.03, 95% CI 1 - 4 mmHg), and 2.5 h (P = 0.05, 95% CI 1 - 4 mmHg) (Figure 2). Mean 
HR tended to be lower overall after NO3- ingestion (P = 0.07) but there was no significant 
 
 
main effect for HR at any specific time point (all P > 0.05). There were no significant 
differences between males and females for any variable (all P > 0.05). 
 
Figure 2. Graphs show change in NO metabolites from baseline after ingestion of beetroot juice. Salivary nitrite 
(A), plasma nitrite (B), salivary nitrate (C) and plasma nitrate (D). * denotes significant increase from baseline 
(P<0.05).   
 
 
 
Figure 3. Graphs show change in BP from baseline to 3.5 h after ingestion of beetroot juice. SBP (A), DBP (B) 
and MAP (C). Value shown are mean ± SD, * denotes significant decrease from baseline, (P < 0.05).   
 
Comparison of nitrate reducing communities of healthy human tongues 
After quality filtering of the data and removal of singleton reads, tongue scrapings of 24 
subjects were included in the analysis. Alpha diversity metrics revealed that samples were 
diverse with an average of 1165 ± 157 OTUs. The Shannon diversity index was 5.2 ± 0.6, 
however, there was notable variation in relative abundance. Previous in vitro work [21]  
suggests that the genera displayed in Table 1 contribute to NO3-  reduction. Some of these 
 
 
were amongst the top five most abundant genera as indicated by the blue shaded area (Table 
1).  
 
Table 1, % relative abundance of genera present in our samples which 
have previously been implicated in nitrate reduction. The blue shaded 
area indicates the top five most abundant genera identified overall.  
OTU ID 
Mean ± 
SD (%)   Max (%)  Min (%) 
Prevotella 42.12 ± 10.09 63.43 19.92 
Veillonella 20.55 ± 12.31 45.5 6.07 
Leptotrichia 4.13 ± 4.11 13.91 0.02 
Fusobacterium 3.60 ± 3.89 13.56 0.01 
Haemophilus 2.84 ± 1.63 6.06 0.00 
Neisseria 2.60 ± 5.50 20.54 0.00 
Actinomyces 0.84 ± 3.77 14.52 0.05 
Porphyromonas 0.47 ± 0.81 2.6 0.00 
Rothia 0.41 ± 0.53 20.54 0.00 
Granulicatella 0.14 ± 0.14 0.014 0.00 
 
We found seven of fourteen known species which have previously been identified as having a 
NO3- reduction gene (Table 2). It has been suggested that bacteria do not work independently 
but as consortium. To reflect this, we calculated the total % relative abundances of the seven 
NO3- reducing bacteria shown in Table 2. We assessed if gender influenced the abundance of 
nitrate reducing bacteria finding that there were no significant differences (P > 0.05).   
 
Table 2, % relative abundance of NO3- reducing species  
Species Mean ± (%) 
Prevotella melaninogenica 31.43 ± 10.33 
Veillonella dispar 19.30 ± 11.97 
Haemophilus parainfluenzae 2.78 ± 3.83  
Neisseria subflava 2.57 ± 5.52 
Veillonella parvula 0.24 ± 0.46 
 
 
Rothia mucilaginosa 0.37 ± 0.49 
Rothia dentocariosa 0.003 ± 0.004  
 
High abundance of nitrate reducing bacteria correlates with high salivary nitrite 
response 
The correlation analysis between the sum of the NO3- reducing species (identified in Table 2) 
and the peak delta change in relevant physiological measurements are displayed in Figure 4. 
The abundance of NO3- reducing bacteria was significantly correlated with the change in 
salivary NO2- (P = 0.03, r = 0.44, Fig. 3A) but not with any other variable (all P > 0.05). The 
area under the curve for salivary NO2- (3010 ± 614.52 µM) was also significantly correlated 
with the sum of the NO3- reducing species (P = 0.05, r = 0.40). 
 
 
   
Figure 4. Correlations between the sum of NO3- reducing bacteria and peak change in salivary NO2- (A) plasma 
NO2- (B), salivary NO3- (C), plasma NO3- (D). * denotes significance, (P<0.05).   
 
Impact of bacterial abundance on pharmacokinetics and pharmacodynamics following 
acute NO3- ingestion 
Seven participants were identified as having less than 50% total relative abundance of the 
NO3-  reducing species identified in their tongue scrapes and were classified to the Low 
group. The remaining participants were classified as the High group. At the OTU level, 
40.99% ± 6.11% NO3-  reducing species were observed in the Low group compared with 
62.64% ± 6.92% in the High group (Figure 5).  
 
 
 
 
Figure 5. A comparison of the relative abundance of NO3- reducing species between those classified as having a 
high (>50%) or low (<50%) overall abundance of NO3- reducing bacteria. Data are presented as group means 
with S.D. excluded for clarity. Rothia dentocariosa is not shown due to low abundance (high group 0.003 ± 
0.001 %, low group 0.002 ± 0.001 %).  
 
At both species and genera level, the sum of NO3- reducing bacteria was significantly higher 
in the High group compared to the Low (species level: P < 0.05, 95% CI 15 ± 28%; genus 
level P < 0.05, 95% CI 11 ± 21%). Alpha diversity metrics revealed that bacterial species in 
the tongue scrape samples of the Low group were more diverse than the high group (P < 
0.001, 1279 ± 136 vs. 1098 ± 129 OTUs, respectively). The Shannon diversity index was also 
higher in the Low group compared to the High group (P = 0.002, 5.9 ± 0.0 vs. 4.9 ± 0.6, 
respectively). There were no differences in the consumption of high, medium, and low NO3- 
vegetables or cured meats between groups. Nor was there any difference in baseline values 
for any physiological variable (all P > 0.05, Table 3). 
 
 
 
 
Table 3, baseline values for the high and low groups. Values are mean ± 
standard error of the mean 
 
High Group 
Mean ± SEM 
Low Group 
Mean ± SEM 
SBP (mmHg) 120 ± 3 123 ± 4 
DBP (mmHg) 68 ± 16 71 ± 27 
MAP (mmHg) 85 ± 2 88 ± 3 
Salivary Nitrite (µM) 227 ± 43 168 ± 97 
Salivary Nitrate (µM) 933 ± 226 549 ± 207 
Plasma Nitrite (nM) 131 ± 32 151 ± 61 
Plasma Nitrate (µM) 39 ± 10 27 ± 11 
 
Salivary NO2- peaked earlier in the High group (1.6 ± 1 h) compared to the Low (3 ± 0.6 h, P 
= 0.04). Salivary NO2- was significantly higher in the High group compared to Low at 1.5 h 
(P = 0.02, 95% CI 130 ± 1320 µM) and 2 h (P = 0.01, 95% CI 182 ± 1375 µM) after 
ingestion of beetroot juice. There were no other differences between groups for salivary NO3- 
or plasma NO metabolites (all P > 0.05) (Figure 6). The time to peak for salivary NO3-, 
plasma NO metabolites, and BP measurements were also not different between groups (all P 
>  0.05).  
 
 
 
 
Figure 6. Change relative to baseline in salivary NO2- (A), plasma NO2- (B), salivary NO3- (C), plasma NO3- (D). 
Data are displayed as means and standard error of the mean. * denotes significant differences between groups, 
(P < 0.05).  
 
Discussion 
Despite the emergent importance of the enterosalivary NO3-, NO2- to NO pathway for 
cardiovascular health, no study has directly investigated the association between the 
abundance of NO3- reducing bacteria in the oral cavity and the capacity to reduce exogenous 
NO3- to NO2-  in vivo. Guided by previous work [20], [21], [36], we first investigated the 
abundance of known NO3- reducing bacteria through 16s rRNA gene sequencing. We provide 
descriptive data at both genus and species level in a much larger sample size than has been 
reported previously in healthy humans. In addition, this is the first description of sequencing 
 
 
data in conjunction with in vivo measurements to demonstrate that the abundance of NO3- 
reducing bacteria on the dorsal surface of the tongue significantly correlates with salivary 
NO2- generation following the ingestion of NO3- rich beetroot juice. A higher abundance of 
these bacteria also results in a more rapid reduction of salivary NO3- to NO2-. Despite this, 
higher abundance of oral NO3- reducing bacteria does not appear to exaggerate changes in 
plasma NO2- or BP following ingestion of beetroot juice, at least in this young healthy cohort. 
 
16S rRNA gene sequencing analysis of the healthy human tongue microbiome 
Our samples were similar in bacterial diversity to those reported previously [21], [37]. At the 
genus level, all genera previously implicated in NO3- reduction [20], [21] were detected. 
Prevotella and Veillonella were found to be the first and second most abundant genera in our 
samples, respectively. In contrast, previous research has typically identified Veillonella as the 
most abundant taxa found on the tongue dorsum [21]. Although direct comparison cannot be 
made between studies due to differences in sequencing platforms and culturing methods, 
these findings support the notion that the composition of the microbiome may differ 
profoundly, even in healthy individuals [38]. 
 
Through 16s RNA sequencing we identified only seven of fourteen known species which 
have previously been demonstrated to reduce NO3- in vitro (Table 2) [21]. In this previous 
work, three tongue scrape samples were analysed using whole genome shotgun sequencing 
(WGS) to identify bacterial species followed by metabolic pathway reconstruction to 
determine NO3- reduction capacity. Given that WGS sequences all genes rather than the more 
targeted approach of 16s RNA sequencing, this method allows for a more accurate taxonomic 
 
 
assignment at species level and likely explains the disparity in the experimental outcomes. 
Nevertheless, we analysed a far greater number of samples (n=24) than has been reported in 
previous research [21] which seems necessary given the aforementioned variability in the 
abundance of bacterial species within the oral microbiome.  
 
Impact of bacterial abundance on the reduction of salivary NO3- to NO2- 
Next, we examined how the abundance of NO3- reducing bacteria influenced 
pharmacokinetics and pharmacodynamics following ingestion of a standardised dietary NO3- 
dose. In line with previous research [26], [27], [39] , the ingestion of NO3- rich beetroot juice 
resulted in a marked elevation of NO metabolites in the plasma and saliva. A novel finding of 
this study is that the abundance of known oral NO3- reducing bacteria was associated with the 
peak increase in salivary NO2- concentration following ingestion of dietary NO3-. 
Furthermore, NO2- peaks earlier in the saliva following ingestion of beetroot juice in 
individuals who have a higher abundance of these bacteria. These data are perhaps 
unsurprising given that oral bacteria are known to play a crucial role in the reduction of 
salivary NO3- to NO2-  [26]±[28]. Nevertheless, where previous research has established that 
the presence of NO3- reducing bacteria is essential, we show that the abundance of these 
bacteria seems to impact the magnitude of salivary NO2- accumulation in the presence of 
elevated salivary NO3-. It is, however, important to acknowledge that these analyses do not 
necessarily LPSO\³FDXVH-HIIHFW´ relationship between bacterial abundance and salivary NO2- 
generation. Other factors, including the efficiency of NO3-  transport via sialin in the salivary 
glands [9], [40], inhibition of stomach acid production [41], and the metabolic activities of 
bacteria [21], may also influence this process. Our findings contrast with previous in vitro 
analysis of three isolated samples which suggested that the NO3- reducing capacity of oral 
 
 
bacterial species was not influenced by the metabolic pathway coverage or the abundance of 
these bacteria [21]. It is evident, therefore, that whilst computational and in vitro methods are 
useful in determining characteristics of microbes in a controlled environment, there is a 
further challenge in determining the functional capacity of a microbial community, especially 
when attempting to relate outcomes to the dynamic in vivo environment.   
 
Impact of bacterial abundance on plasma pharmacokinetics and BP 
Despite the association with salivary NO2-, the abundance of NO3- reducing bacteria was not 
related to the change in plasma NO2- or BP markers. Nor did a higher abundance of these 
bacteria alter plasma pharmacokinetics following the ingestion of beetroot juice. This has 
important implications since plasma NO2- is considered to provide the best approximation of 
circulating NO bioavailability [42], [43] and is suggested to be a marker of endothelial 
function [44] and cardiovascular risk [45]. While some have proposed that salivary NO2- may 
be a useful point of care diagnostic for assessing total body NO bioavailability [46], the 
discordance between salivary and plasma changes in NO2- observed in the present study 
would seem to refute this suggestion for healthy young subjects.  
 
Our data suggests that, at least in this homogenous sample, higher abundance of NO3- 
reducing bacteria does not seem to further increase circulating NO bioavailability. Whilst it is 
useful to characterise the healthy human microbiome in this context, it is necessary to further 
explore these data in populations with compromised NO bioavailability, including older 
adults [47], patients with endothelial dysfunction [48], and those treated with antibiotics [49] . 
Furthermore, it should be acknowledged that while some participants were classified as 
 
 
KDYLQJD³ORZ´DEXQGDQFHRI123- reducing bacteria, this cohort still had 41 ± 6% of taxa 
which possess a NO3- reductase gene (with the lowest abundance being 29%) and all 
experienced a substantial increase in plasma NO metabolites. Previous work by Woessner 
and colleagues [28] demonstrated a stepwise reduction in salivary NO2-   and BP responses 
when differing strengths of mouthwash were administered which further supports the notion 
that the magnitude of NO3- conversion is related to the abundance of NO3- reducing bacteria. 
The apparent consequence of the lower abundance of these bacteria is that salivary NO3- 
reduction occurs at a slower rate than those in the high group but the appearance of salivary 
NO2- can continue to accelerate at least up to 3 h after ingestion of a NO3- dose. It would, 
therefore, be of interest to collect further data from individuals with an altered microbiome 
such as that which might occur with ageing [23][22] or periodontal disease [50]. 
 
There are a number of reasons why an augmented salivary NO2- concentration was not 
paralleled by the expected additional increase in plasma NO2- but these remain speculative 
until further experimental data is collected. Firstly, it may be WKDW ³H[FHVV´ NO2- from the 
saliva is excreted via the urinary system. NO3- and NO2-,  originating from either exogenous 
and endogenous sources, have been shown to be excreted in the urine [51]. This suggests that 
there may be a saturation threshold for circulating NO2- over which the excess is either stored 
or excreted. This may be to prevent excessive drops in BP which would be detrimental to 
homeostasis [52]. Future studies could include urine collection and analysis to verify this 
hypothesis. Alternatively, the lack of accordance between oral bacterial abundance and 
plasma NO2- may be due to the generation of NO2- at sites outside the oral cavity. NO3- 
reduction is thought to occur in the gastrointestinal tract, for example, through conversion to 
bioactive nitrogen oxides via hydrogen chloride [1]. Vermerien and colleagues [53] also 
showed that, in conditions simulating the colon, faecal microbiota can reduce NO3- to NO via 
 
 
dissimilatory reduction to ammonia. Given that NO possesses a very short in vivo half-life it 
may then be rapidly oxidised back to NO2- and NO3- [43][42][41][40]. It must also be 
acknowledged that there are many storage forms of NO in the red blood cells and plasma that 
may exert physiological effects, including s-nitrosothiols [41] and nitrated lipids [54] It is 
possible, therefore, that plasma NO2- may simply be a marker of NO availability [41] and not 
the intermediate directly responsible to the reduction in BP resulting from NO3- administration. 
 
Conclusions 
We show in vivo in healthy adults that there is a positive linear relationship between the total 
relative abundance of commensal NO3- reducing oral bacteria and the generation of salivary 
NO2- following a dose of dietary NO3-. While these data are cross-sectional and correlative in 
nature, these findings are significant given the supposed therapeutic benefits of dietary NO3- 
supplementation. Nevertheless, a higher relative abundance of NO3- reducing bacteria did not 
result in further increases in plasma NO2- concentration (a marker of vascular NO 
bioavailability) and nor did it influence the extent by which BP was reduced following 
ingestion of NO3--rich beetroot juice. This suggests that where sufficient quantities of these 
bacteria are present on the tongue, dietary NO3- supplementation will consistently increase 
circulating NO with potentially meaningful biological consequences. Further work should 
explore these phenomena in populations with compromised endogenous NO generation 
capacity or with an altered oral microbiome to better understand the link between commensal 
bacteria and cardiovascular health. 
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Highlights 
x Prevotella are the most abundant genera of nitrate-reducing bacteria in the mouth  
x Abundance of nitrate-reducing bacteria is associated with the generation of nitrite  
x Abundance of these bacteria is not associated with plasma nitrite concentration 
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